Impact of drug-resistance polymerase mutations on the replication of HBeAg-positive and HBeAg-negative hepatitis B virus strains in vitro

Hepatitis Monthly

Volumn 12, Issue 6, 2012, Pages 77-79

  Tacke, Frank ^a   Shirvani Dastgerdi, Elham ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ACUTE ON CHRONIC LIVER FAILURE; BASAL CORE PROMOTER GENE; EDITORIAL; GENE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; PRECORE GENE; RISK FACTOR; STRUCTURAL GENE; VIRUS REPLICATION;

EID: 84864477516     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.862     Document Type: Editorial

References (19)

1. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro- Mediterranean and African countries. J Hepatol 2011;55:183-191.
2. Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, Derakhshan F, Chiani M, Rostami Nejad M, et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect 2008;14:858-866.
3. Tacke F, Manns MP, Trautwein C. Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies. Curr Med Chem 2004;11:2667-2677.
4. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011;26:628-638.
5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
6. Xiao L, Zhou B, Gao H, Ma S, Yang G, Xu M, Abbott WG, et al. Hepatitis B virus genotype B with G1896A and A1762T/G1764A mutations is associated with hepatitis B related acute-on-chronic liver failure. J Med Virol 2011;83:1544-1550.
7. Xu Z, Ren X, Liu Y, Li X, Bai S, Zhong Y, Wang L, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol 2011;46:391-400.
8. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101:1066-1082.
9. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
10. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, et al. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol 2011;49:871-930.
11. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-8535.
12. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WET, Isom H, Bowden S, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37:27-35.
13. Amini-Bavil-Olyaee S, Sheldon J, Lutz T, Trautwein C, Tacke F. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS 2009;23:268-272.
14. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol 2010;84:1026-1033.
15. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigenpositive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-1165.
16. Zhu Y, Curtis M, Borroto-Esoda K. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations. Antivir Chem Chemother 2011;22:13-22.
17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
18. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507.
19. Amini-Bavil-Olyaee S, Herbers U, Luedde T, Trautwein C, Tacke F. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. J Viral Hepat 2011;18:804-814.